文献速递肿瘤 PET/CT核素与放射性配体治疗

肽受体放射性核素治疗在寡不一致性胃肠胰神经内分泌肿瘤中的疗效

Efficacy of peptide receptor radionuclide therapy in patients with oligodiscordant gastroenteropancreatic neuroendocrine tumours.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-07-06

本研究首次回顾性描述接受至少一周期[177Lu]Lu-DOTA-TATE治疗的晚期胃肠胰神经内分泌肿瘤寡不一致性疾病患者的治疗模式与结局。13例患者中位总生存27.3个月,中位无进展生存15.1个月,中位至下一治疗时间15.0个月,无显著肾毒性。

要点

  • PRRT联合系统治疗或其他治疗在寡不一致性NET中有效且毒性可接受。
  • 中位PFS为15.1个月,中位OS为27.3个月。
  • 长期随访中1/15例发生治疗相关髓系肿瘤,无显著肾毒性。

核心结论

  • 对于双PET显像发现的晚期寡不一致性NET患者,PRRT联合系统治疗或其他治疗(手术、肝脏定向治疗、放疗)有效且毒性可接受,可考虑作为选定患者的治疗选择。
  • 治疗模式的顺序和具体策略最好在具有多学科输入的富经验NET中心决定。

研究设计与样本

  • 单中心回顾性综述,纳入2020至2024年接受至少一周期[177Lu]Lu-DOTA-TATE治疗的晚期胃肠胰NET寡不一致性疾病患者。
  • 共13例患者符合纳入标准,中位年龄66岁,54%为男性。
  • 安全性通过PRRT期间及治疗完成后3个月的肾脏和血液学参数(CTCAE v5.0)评估。
  • 治疗反应通过Gallium-68 DOTATATE PET/CT分子影像评估。
  • 采用Kaplan-Meier法进行中位PFS、OS和TTNT分析。

主要发现

  • 原发部位:小肠7例,胰腺4例,结直肠2例。
  • 中位OS为27.3个月(95% CI 19.7 - 未达到),中位PFS为15.1个月(95% CI 7.1-20.1),中位TTNT为15.0个月(95% CI 6.7-39.6)。
  • 长期随访中15例患者中有1例发生治疗相关髓系肿瘤,经骨髓活检确认。
  • 随访中无患者发生显著肾毒性。

临床怎么用

  • 在双PET显像识别出寡不一致性疾病的晚期NET患者中,可考虑PRRT联合系统治疗或其他治疗。
  • 治疗策略应在富经验NET中心经多学科讨论决定。

局限性

  • 单中心回顾性研究,样本量小(13例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of peptide receptor radionuclide therapy (PRRT) is well established in the treatment of advanced or unresectable neuroendocrine tumours (NETs) after progression on somatostatin analogues (SSA), with randomised clinical trials such as NETTER-1 and NETTER-2 showing improvement in progression free survival (PFS) as well as tumour response [12, 13]. Current landmark trials only considered patients suitable for PRRT if all known lesions displayed SSTR expression, via avidity on planar scintigraphy or Gallium-68 DOTATATE PET/CT. However, there is a select group of patients with oligodiscordant disease (3 or less lesions which are FDG avid but not DOTATATE avid) on dual DOTATATE/FDG PET imaging who may benefit from PRRT in combination with additional therapies such as liver directed therapy (LDT) or chemotherapy. There is currently no data regarding the efficacy and outcomes of PRRT in oligodiscordant disease. This study is the first to describe the treatment patterns and outcomes of patients with oligodiscordant disease receiving PRRT. METHODS: A single-centre retrospective review was performed in patients with advanced gastroenteropancreatic NETs with oligodiscordant disease who received at least one cycle of PRRT with [177Lu]Lu-DOTA-TATE from 2020 to 2024. Safety was assessed by renal and haematological parameters (CTCAE v5.0) during PRRT, and at 3 months post completion of treatment. Response to treatment was evaluated on molecular imaging with Gallium-68 DOTATATE PET/CT. Kaplan-Meier method was used to perform median progression free survival (PFS), overall survival (OS), and time to next treatment (TTNT) analyses. RESULTS: Thirteen patients met the inclusion criteria, the median age was 66 years, and 54% were male. Primary site: small bowel (7), pancreas (4), colorectal (2). WHO grade: none had grade 1 disease, ten grade 2 and three had grade 3 disease. Median OS was 27.3 months (95% CI 19.7 - not reached), median PFS 15.1 months (95% CI 7.1-20.1), and median TTNT 15.0 months (95% CI 6.7-39.6). One of 15 patients developed treatment related myeloid neoplasm on long term follow-up, confirmed by bone marrow biopsy. No patients developed significant renal toxicity on follow-up. CONCLUSION: In patients with advanced NETs with oligodiscordant disease identified on dual PET imaging, the combination of PRRT with systemic therapy or other therapies (surgery, liver directed therapy, radiotherapy) can be effective with acceptable toxicity and should be considered as a possible option for treatment in selected patients. The sequencing of treatment modalities and exact strategy employed is best decided at an experienced NET centre with multi-disciplinary input.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Mok C, Chow W, Sabahi Z, et al. Efficacy of peptide receptor radionuclide therapy in patients with oligodiscordant gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2026. PMID: 42402519. doi:10.1007/s00259-026-08042-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。